Phase 2, Phase 3 Recruiting Network
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in Texas: - Hendrick Medical Center — Abilene, Texas
- The Don and Sybil Harrington Cancer Center — Amarillo, Texas
- Parkland Memorial Hospital — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas
Phase 2, Phase 3 Recruiting NIH
This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04402788
Sites in Texas: - MD Anderson in The Woodlands — Conroe, Texas
- Texas Oncology-Flower Mound — Flower Mound, Texas
- Texas Oncology - Fort Worth Cancer Center — Fort Worth, Texas
- M D Anderson Cancer Center — Houston, Texas
- MD Anderson West Houston — Houston, Texas
Phase 3 Recruiting Academic/Other
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632327
Sites in Texas: - UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- Lyndon Baines Johnson General Hospital — Houston, Texas
Phase 3 Recruiting Network
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…
Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Sites in Texas: - Texas Tech University Health Sciences Center-Amarillo — Amarillo, Texas
- Dell Children's Medical Center of Central Texas — Austin, Texas
- Driscoll Children's Hospital — Corpus Christi, Texas
- Medical City Dallas Hospital — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
Phase 3 Recruiting Industry
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…
Sponsor: Pfizer
NCT ID: NCT07144280
Sites in Texas: - Texas Oncology - West Texas — Abilene, Texas
- Texas Oncology-Northeast Texas — Allen, Texas
- Texas Oncology- Central South. — Austin, Texas
- Texas Oncology Central South — Austin, Texas
- Texas Oncology- Central South. — Austin, Texas
Phase 3 Recruiting Industry
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Sites in Texas: - Clinical Study Site — Abilene, Texas
- Clinical Study Site — Austin, Texas
- Clinical Study Site — Dallas, Texas
- Clinical Study Site — Forth Worth, Texas
- Clinical Study Site — Houston, Texas
Phase 3 Recruiting Industry
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if ol…
Sponsor: Eli Lilly and Company
NCT ID: NCT06890598
Sites in Texas: - The Center for Cancer and Blood Disorders — Fort Worth, Texas
- Houston Methodist Hospital — Houston, Texas
- University of Texas MD Anderson Cancer Center — Houston, Texas
- USO - Texas Oncology - San Antonio — San Antonio, Texas
- USO - Texas Oncology Gulf Coast — Sugar Land, Texas
Phase 3 Recruiting Industry
This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary en…
Sponsor: Summit Therapeutics
NCT ID: NCT05899608
Sites in Texas: - Texas Oncology- Austin — Austin, Texas
- Texas Oncology-Dallas — Dallas, Texas
- UT Southwestern Medical Center — Dallas, Texas
- Houston Methodist Hospital — Houston, Texas
- MD Anderson Cancer Center — Houston, Texas
Phase 3 Recruiting Industry
TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable gen…
Sponsor: AstraZeneca
NCT ID: NCT07291037
Sites in Texas: - Research Site — Austin, Texas
- Research Site — Denton, Texas
- Research Site — Plano, Texas
Phase 3 Recruiting Industry
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…
Sponsor: AbbVie
NCT ID: NCT04928846
Sites in Texas: - Dell Seton Medical Center /ID# 247016 — Austin, Texas
Phase 3 Recruiting Industry
This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tir…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06312137
Sites in Texas: - Millennium Research & Clinical Development ( Site 0039) — Houston, Texas
Phase 3 Recruiting Industry
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in Texas: - Texas Oncology - DFW ( Site 8103) — Dallas, Texas
- UT Southwestern Medical Center ( Site 0190) — Dallas, Texas
- Houston Methodist Cancer Center ( Site 0191) — Houston, Texas
- MD Anderson Cancer Center ( Site 0150) — Houston, Texas
- Memorial Hermann Cancer Center ( Site 0172) — Houston, Texas
Phase 3 Recruiting Industry
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untr…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT06875310
Sites in Texas: - Local Institution - 0692 — Galveston, Texas
- Local Institution - 0652 — Laredo, Texas
- Local Institution - 0622 — San Antonio, Texas
Phase 3 Recruiting Academic/Other
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Sponsor: University of Texas Southwestern Medical Center
NCT ID: NCT02468024
Sites in Texas: - Cardiothoracic and Vascular Surgeons — Austin, Texas
- University of Texas Southwestern Medical Center — Dallas, Texas
Phase 3 Recruiting Industry
The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).
Sponsor: Amgen
NCT ID: NCT07005128
Sites in Texas: - Texas Oncology — Dallas, Texas
- Oncology Consultants — Houston, Texas
- US Oncology Research Investigational Products Center — Irving, Texas
- Texas Oncology Northeast Texas — Tyler, Texas
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to compare the clinical benefit of the combination of BMS-986504 (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07063745
Sites in Texas: - Local Institution - 0433 — Dallas, Texas
- Local Institution - 0374 — El Paso, Texas
- University of Texas MD Anderson Cancer Center — Houston, Texas
- Local Institution - 0377 — The Woodlands, Texas
Phase 3 Recruiting Industry
The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally advanced o…
Sponsor: AstraZeneca
NCT ID: NCT06350097
Sites in Texas: - Research Site — Dallas, Texas
- Research Site — Houston, Texas
- Research Site — Houston, Texas
- Research Site — Webster, Texas
- Research Site — Woodway, Texas
Phase 3 Recruiting Industry
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in Texas: - MD Anderson Cancer Center - University of Texas — Houston, Texas
Phase 2, Phase 3 Recruiting Industry
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…
Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in Texas: - Millennium Research and Clinical Development, LLC — Houston, Texas
Phase 3 Recruiting Academic/Other
The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation thera…
Sponsor: Shanghai Junshi Bioscience Co., Ltd.
NCT ID: NCT06095583
Sites in Texas: - Millennium Physicians - Oncology — Houston, Texas
- Texas Oncology, P.A. - Oncology — Tyler, Texas
Phase 2, Phase 3 Recruiting Industry
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07100080
Sites in Texas: - Local Institution - 0025 — Houston, Texas
- Local Institution - 0173 — San Antonio, Texas
Phase 3 Recruiting Industry
This study is open to adults 18 years and older who have early-stage non-small cell lung cancer (NSCLC). Their cancer must have a specific change in a gene called HER2. Genes provide the instructions for making proteins, and this change le…
Sponsor: Boehringer Ingelheim
NCT ID: NCT07195695
Sites in Texas: - Hendrick Health — Abilene, Texas
Phase 3 Recruiting Industry
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung cancer (E…
Sponsor: Gilead Sciences
NCT ID: NCT06801834
Sites in Texas: - Hendrick Health System — Abilene, Texas
- MD Anderson Cancer Center — Houston, Texas
- Texas Oncology - San Antonio — New Braunfels, Texas
- The University of Texas Health Science Center at Tyler — Tyler, Texas
Phase 3 Recruiting Industry
The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet ch…
Sponsor: Amgen
NCT ID: NCT05920356
Sites in Texas: - Oncology Consultants PA — Houston, Texas
- University of Texas MD Anderson Cancer Center — Houston, Texas
- US Oncology Research Investigational Products Center — Irving, Texas
Phase 3 Recruiting Industry
The purpose of this study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squamous non-small cell lung cancer (NSCLC…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06305754
Sites in Texas: - John Peter Smith Hospital ( Site 0065) — Fort Worth, Texas
- University of Texas MD Anderson ( Site 0063) — Houston, Texas
- Millennium Research & Clinical Development ( Site 0035) — Houston, Texas